Figure 2From: Therapeutic targeting of cancer cell cycle using proteasome inhibitors MAPK pathways and Proteasome inhibitors: Proteasome inhibitors modulate the members of MAPK pathway and control cell cycle of cancer cells. PIs inhibit the activation of ERK 1/2 protein, which is found to increase the expression of cyclin D1. PIs activate p38 MAPK which antagonizes the effect of ERK 1/2 and decrease cyclin D1. PIs also activate JNK which is known to inhibit the E2F activity.Back to article page